Podcast Interview: Chris Garabedian, CEO, AVI BioPharma

Article

In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Interview: Chris Garabedian

Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Recent Videos
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Related Content